奥扎格雷钠联合氯比格雷对非ST段抬高型急性冠脉综合征患者血清hs-CRP,MMP-9和sCD40L的影响(1)
 |
| 第1页 |
参见附件。
【摘要】目的 探讨奥扎格雷钠联合氯比格雷对非ST段抬高型急性冠脉综合征患者血清超敏C反应蛋白(hs-CRP),金属蛋白酶9(MMP-9)和可溶性CD40配体(sCD40L)的影响。 方法 82例非ST段抬高型的急性冠脉综合征患者随机分为两组，对照组40例，采用常规治疗，治疗组42例，采用常规治疗加用奥扎格雷钠和氯比格雷，两组共治疗14 d。测定两组患者治疗前后血清的hs-CRP.MMP-9和sCD40L的表达。 结果 两组治疗后均明显降低血清hs-CRP,MMP-9和sCD40L的表达，并且治疗组改善hs-CRP,MMP-9和sCD40L的表达均明显优于对照组( P <0.05)。 结论 奥扎格雷钠联合氯比格雷可以明显减少非ST 段抬高型急性冠脉综合征患者血清hs-CRP,MMP-9和sCD40L的表达，从而可以改善病情。
【关键词】 奥扎格雷钠；氯比格雷；急性冠脉综合征；超敏C反应蛋白；金属蛋白酶9；可溶性CD40配体
The effectiveness of sodium ozagrel plus clopidogrel on the hs-CRP,MMP-9 and sCD40L in the serum of patients with non-ST-segment elevation acute coronary syndrome LI Lai-shi. Xinwen Mining Group,The Cardiology of Laiwu Center Hospital,Shandong 271103,China
【Abstract】 Objective To study the effectiveness of sodium ozagrel plus clopidogrel on the high sensitivity C-reactive protein(hs-CRP),met alloproteinase-9(MMP-9) and soluble CD40 ligand(sCD40L) in the serum of patients with non-ST-segment elevation acute coronary syndrome. Methods Eighty-two patients with non-ST-segment elevation acute coronary syndrome were randomly divided into two groups,the control group(n=40 cases) and the treatment group(n=42 cases).The patients in the control group were treated through the conventional treatment and the patients in the treatment group were treated through sodium ozagrel plus clopidogrel except the conventional treatment.They were treated for forteen days.The hs-CRP,MMP-9 and sCD40L in the serum were detected before and after treatment. Results The hs-CRP,MMP-9 and sCD40L in the serum were all lowed after treatment in both groups. The hs-CRP,MMP-9 and sCD40L in the treatment were improved significantly more than those of the control group( P <0.05). Conclusion Sodium ozagrel plus clopidogrel can significantly decrease the hs-CRP,MMP-9 and sCD40L in the serum of patients with non-ST-segment elevation acute coronary syndrome ......
您现在查看是摘要介绍页，详见PDF附件(3941kb)。